Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

EGFR Inhibition in RAS Wild-Type Unresectable mCRC

July 16th 2015

Daily Aspirin for Colorectal Cancer Prevention

July 16th 2015

Impact of the SIRFLOX Study on CRC Management

July 16th 2015

Role of Surgery in Metastatic Colorectal Cancer

July 16th 2015

Broad Molecular Profiling in Colorectal Cancer

July 16th 2015

Genetic Testing in Colorectal Cancer

July 16th 2015

Van Cutsem Discusses Regorafenib, Emergence of Precision Medicine in mCRC

July 16th 2015

Eric Van Cutsem, MD, PhD, discusses results from the phase IIIb CONSIGN study and the continuing advance of precision medicine in colorectal cancer.

PD-1 Blockade Effective in Mismatch Repair-Deficient CRC

July 15th 2015

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.

Colorectal Experts Discuss the ASCO Annual Meeting

July 13th 2015

Actionable Molecular Testing in CRC

July 13th 2015

Upfront Treatment Strategies for Metastatic Colorectal Cancer

July 13th 2015

Maintenance Therapy in Colorectal Cancer

July 13th 2015

Frontline Treatment Selection in RAS Wild-Type mCRC

July 13th 2015

TAS-102 in Metastatic Colorectal Cancer

July 13th 2015

SIRFLOX Study in Metastatic Colorectal Cancer

July 13th 2015

Regorafenib in Metastatic Colorectal Cancer

July 13th 2015

Mismatch Repair Deficiency in Colorectal Cancer

July 13th 2015

Adjuvant Aspirin in Colorectal Cancer

July 13th 2015

Dr. Argilés on BRAF-Mutations in Colorectal Cancer

July 10th 2015

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

2015 World Congress on GI Cancer

July 9th 2015

NEXT PAGE
PREVIOUS PAGE